FDA names former pharmaceutical company executive to oversee US drug program
FDA Commissioner Marty Makary announced that Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency's Center for Drug Evaluation and Research, which regulates the safety and effectiveness of all U.S. drugs.
His appointment comes a month after the center's acting director, Dr. Jacqueline Corrigan-Curay, announced her retirement.
As the agency's top drug regulator, Tidmarsh will be charged with following through on a number of commitments made by Makary and his boss, Health Secretary Robert F. Kennedy Jr., including reviewing the safety of the abortion pill mifepristone. The FDA is also scrutinizing certain uses of other long-established drugs, including antidepressants and hormone-replacement drugs for menopause.
Tidmarsh founded and led several pharmaceutical companies, including Horizon Pharmaceuticals, maker of an anti-inflammatory medication for arthritis. He has also served as an adjunct professor at Stanford University.
The FDA's drug center is the agency's largest unit, with nearly 6,000 staffers responsible for reviewing the safety and effectiveness of new drugs and monitoring the use and marketing of older drugs.
About 2,000 FDA staffers have been laid off as part of widescale cuts to the federal health workforce overseen by Kennedy. More than 1,000 others have taken buyouts or early retirement, while many others are reportedly searching for new jobs. The departures have threatened basic FDA operations, including the timely review of new drugs.
Nearly all of the FDA's senior leadership positions have turned over in recent months, either due to retirements, resignations or actions by administration officials placing them on administrative leave.
FDA center directors typically hold their positions for years or even decades, serving across multiple administrations, whether Republican or Democrat.
In May, Makary named Dr. Vinay Prasad, a prominent critic of the FDA's COVID response, to run the agency's vaccine center. He was also named to the post of FDA chief medical officer. Prasad joined the agency after his predecessor, longtime vaccine chief Dr. Peter Marks, was forced out in March.
The head of FDA's tobacco center was also forced to step down in April. A permanent replacement has not yet been named.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
a minute ago
- New York Times
What Happens When Doctors Can't Trust the Government?
The other day I was talking to one of my patients about her vaccinations, and I noticed that she hadn't had a Covid-19 vaccine since the early days of the pandemic. 'The virus has changed so much since then,' I told her, 'so we recommend that you get the current vaccine——' And then I stopped dead in my tracks, the words 'we recommend' lingering in the air. This is how I'd always phrased these types of recommendations, but I was suddenly unsure of who the 'we' was. Up until recently, it meant a medical community that included not just my health care colleagues, but also the Centers for Disease Control and Prevention, the Food and Drug Administration, the National Institutes of Health, respected medical journals and the research community. It's not remotely feasible for practicing clinicians to review every medical study out there, so we rely on trusted colleagues and institutions with the relevant expertise to help guide us. The 'we' suddenly rang hollow. The institutions I trusted to be deliberative and evidence-based sources of knowledge that extend my medical abilities are no longer that. In the first Trump administration, despite relentless attacks from the president, the nation's public health institutions remained largely intact, if wearied. But the plunder of the second Trump administration has disemboweled them and installed fox-guarding-the-henhouse leadership. Medical professionals can no longer fully trust federal health guidance, and our patients are the ones who will suffer the most. For most of my colleagues and me, the C.D.C. and the N.I.H. were the medical Mount Olympus, the towering pillars of medical authority. Contrary to right-wing portrayals, these were not dictatorial authorities. These were earned authorities, comprising our best, brightest and most dedicated peers. The formidable talents of these doctors and scientists would have commanded enviable salaries had they taken jobs in industry, but they chose the public sector instead — something that we clinicians were forever grateful for. Were there egos, missteps and shortcomings? Sure. But by and large, the people I met who worked for the C.D.C. or N.I.H. were brilliant and rigorous, and cared passionately about the science they were pursuing. While there are some doctors who viewed our public health institutions with disdain — some of them now are running these very organizations — most practicing physicians relied heavily on them to deliver the best care possible to their patients, despite occasional quibbles. What a relief, I always felt, that there were people organizing the things I can't do — testing new treatments, conducting population studies, keeping tabs on worldwide diseases, issuing guidelines and more. Want all of The Times? Subscribe.
Associated Press
a minute ago
- Associated Press
Israeli strikes kill at least 34 people in Gaza, officials say, as some aid restrictions are eased
DEIR AL-BALAH, Gaza Strip (AP) — Israeli strikes killed at least 34 Palestinians in multiple locations across Gaza on Monday, local health officials said, a day after Israel eased aid restrictions in the face of a worsening humanitarian crisis in the territory. Israel announced Sunday that the military would pause operations in Gaza City, Deir al-Balah and Muwasi for 10 hours a day until further notice to allow for the improved flow of aid to Palestinians in Gaza, where concern over hunger has grown, and designate secure routes for aid delivery. Israel said it would continue military operations alongside the new humanitarian measures. The Israeli military had no immediate comment about the latest strikes, which occurred outside the time frame for the pause Israel declared would be held between 10 a.m. and 8 p.m. Aid agencies have welcomed the new aid measures, which also included allowing airdrops into Gaza, but said they were not enough to counter the rising hunger in the Palestinian territory. Images of emaciated children have sparked outrage around the world, including from Israel's close allies. U.S. President Donald Trump on Sunday called the images of emaciated and malnourished children in Gaza 'terrible.' Israel has restricted aid to varying degrees throughout the war. In March, it cut off the entry of all goods, including fuel, food and medicine to pressure Hamas to free hostages. Israel partially lifted those restrictions in May but also pushed ahead on a new U.S.-backed aid delivery system that has been wracked by chaos and violence. Traditional aid providers also have encountered a similar breakdown in law and order surrounding their aid deliveries. Most of Gaza's population now relies on aid. Accessing food has become a challenge that some Palestinians have risked their lives for. The Awda hospital in central Gaza said it received the bodies of seven Palestinians who it said were killed Monday by Israeli fire close to an aid distribution site run by the U.S.- and Israeli-backed Gaza Humanitarian Foundation. The hospital said 20 others were wounded close to the site. Elsewhere, a woman who was seven months pregnant was killed along with 11 others after their house was struck in the Muwasi area, west of the southern city of Khan Younis. The woman's fetus survived after a complex surgery, according to the Palestinian Red Crescent. One strike hit a two-story house in the western Japanese neighborhood of Khan Younis, killing at least 11 people, more than half of them women and children, said the Nasser Hospital, which received the casualties. The Israeli military and GHF did not immediately respond to a request for comment on those strikes. In its Oct. 7, 2023, attack, Hamas killed 1,200 people and took 251 hostages. It still holds 50, more than half Israel believes to be dead. Israel's retaliatory offensive has killed more than 59,800 Palestinians, according to Gaza's Health Ministry. Its count doesn't distinguish between militants and civilians, but the ministry says over half of the dead are women and children. The ministry operates under the Hamas government. The U.N. and other international organizations see it as the most reliable source of data on casualties. ___ Magdy reported from Cairo. ___ Follow AP's war coverage at
Medscape
5 hours ago
- Medscape
More Data Cement COVID's Impact on Patients With Cancer
TOPLINE: New data confirm the impact COVID infection can have on patients with cancer and identified several risk factors associated with hospitalization and death. Receipt of chemotherapy as well as a baseline history of stroke, atrial fibrillation, or pulmonary embolism were each associated with nearly double the risk for COVID-related hospitalization. Prior vaccination halved this risk. Older age and earlier hospitalization were associated with a greater risk for death. METHODOLOGY: Patients undergoing active cancer treatment are at increased risk for severe COVID-19 due to immunosuppression, but risk factors for hospitalization and death are not well-defined. Researchers conducted a prospective cohort study involving 1572 patients with cancer (median age, 60 years; 53.4% women), enrolled within 14 days of a positive SARS-CoV-2 test; participants had received active treatment for cancer within 6 weeks before testing or had undergone prior stem cell transplant or CAR T-cell therapy. Patient screening and enrollment took place between May 2020 and February 2022. Treatments included chemotherapy (34.3%), targeted therapy (27.7%), and immunotherapy (10.6%). Breast (23.6%) and lung (13.9%) cancers were the most common cancer types. Overall, 64% of participants had metastatic disease, and at enrollment, 64% had not received a COVID vaccine. Study outcomes were COVID-related hospitalization or death. Risk factors for hospitalization and for death among hospitalized patients were evaluated separately. TAKEAWAY: At 90 days after an initial positive test, COVID-related mortality was 3% and remained stable at subsequent follow-ups. The highest incidence occurred in patients with lymphoma, followed by those with acute leukemia or lung cancer; the lowest incidence occurred in those with other types of solid tumors and blood cancers. Hospitalization for COVID-19 occurred in 18.4% of patients within 90 days of enrollment. The risk for hospitalization was elevated among patients who received chemotherapy (hazard ratio [HR], 1.97) and those with a history of stroke, atrial fibrillation, and pulmonary embolism (HR, 1.78). Vaccination prior to infection reduced the risk for hospitalization by nearly half (HR, 0.52). Hospitalization for COVID-19 within 30 days of infection was associated with an increased risk for death (HR, 14.6). Among patients hospitalized for COVID within 30 days, age 65 years or older was the only significant predictor of COVID-specific death (HR, 3.49). Over the 2-year follow-up, there were 1739 disruptions to cancer treatment; 50.7% of these were attributed to COVID-19, and most occurred within 30 days of a positive test. IN PRACTICE: 'The data from this prospective cohort study confirm and expand previous retrospective case series that have found factors, including hematologic cancers, chemotherapy receipt, and lung cancer, as associated with COVID-19 severity,' the authors of the study wrote, noting that the results 'showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death.' SOURCE: This study, led by Brian I. Rini, MD, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, was published online in JAMA Oncology. LIMITATIONS: Information on specific strains was not available. This study lacked a control group of patients without COVID-19, which limited causal inference. Additionally, as participants were enrolled through the National Cancer Institute trial networks, generalizability to a broader population could be limited. DISCLOSURES: This study was funded in part by the Coronavirus Aid, Relief, and Economic Security Act and the National Cancer Institute National Clinical Trials Network, Experimental Therapeutics Clinical Trials Network, and Community Oncology Research Program grants via the U10 funding mechanism. Several authors declared receiving grants and/or personal fees and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
